ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
A Nanovaccine Based on Adjuvant Peptide FK-13 and l-Phenylalanine Poly(ester amide) Enhances CD8
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Neurotransmitters in cancer: how receptor signaling and posttranslational modifications modulate tumor progression and offer new therapeutic targets.Cell communication and signaling : CCS · 2026Review
- Development of a Novel Polyleucine-Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- Nanomaterial-assisted immunodiagnostic profiling and therapeutic targeting of hepatocellular carcinoma: from molecular biomarkers to clinical applications.Frontiers in immunology · 2025Article
- Nanovaccines empowering CD8Theranostics · 2025Review
- Nano drug delivery systems for advanced immune checkpoint blockade therapy.Theranostics · 2025Review
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Recent advances in the development of poly(ester amide)s-based carriers for drug delivery.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy.Materials today. Bio · 2024Article
- The quest for nanoparticle-powered vaccines in cancer immunotherapy.Journal of nanobiotechnology · 2024Review
- A Nanovaccine Based on Adjuvant Peptide FK-13 and l-Phenylalanine Poly(ester amide) Enhances CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.Cell & bioscience · 2023Review
- Supramolecular Biomaterials for Cancer Immunotherapy.Research (Washington, D.C.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
Abstract
Cancer vaccines have shown promise as effective means of antitumor immunotherapy by inducing tumor antigen-specific T cell immunity. In this study, a novel peptide-based tumor nanovaccine that boosts antigen presentation and elicits effective antitumor immunity is developed. The adjuvant characteristics of an antimicrobial peptide-derived core peptide, FK-13, are investigated and used it to generate a fusion peptide named FK-33 with tumor antigen epitopes. l-phenylalanine-based poly(ester amide) (Phe-PEA), 8p4, is also identified as a competent delivery vehicle for the fusion peptide FK-33. Notably, the vaccination of 8p4 + FK-33 nanoparticles (8FNs) in vivo induces dendritic cell activation in the lymph nodes and elicits robust tumor antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.